Topotecan for the treatment of relapsed small-cell lung cancer

  • Technology appraisal guidance
  • TA184
  • Published: 
Download guidance (PDF)

6 Recommendations for research

6.1

The Committee noted the following ongoing clinical trials related to this appraisal.

  • NCT00547651 is a phase III, randomised controlled trial comparing intravenous amrubicin (40 mg/m2) with intravenous topotecan (1.5 mg/m2) in adults with extensive-stage or limited-stage small-cell lung cancer sensitive or refractory to first-line (platinum-based) chemotherapy. Estimated study completion date: March 2011.